Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
Precigen, Inc. is holding its 2026 virtual Annual Meeting on June 18, 2026, with April 17, 2026 as the record date. Shareholders will vote on electing nine directors, ratifying Deloitte & Touche LLP, approving 2025 executive compensation on an advisory basis, and amending the 2023 Omnibus Incentive Plan to increase the shares available for awards by 7 million.
Each share of common stock outstanding as of the record date is entitled to one vote, with 356,510,977 shares outstanding at that time. The proxy also reviews corporate governance practices, director and executive pay, beneficial ownership, auditor fees and the company’s 2025 performance, including FDA approval and initial launch of Papzimeos for recurrent respiratory papillomatosis.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr received new equity awards in the form of restricted stock units and stock options. On April 20, 2026, he was granted 107,000 RSUs, each representing one share of common stock, and 358,000 stock options with a $4.11 exercise price.
The RSUs vest 25% on May 23, 2027 and then in equal six‑month installments over three years. The options vest 25% on the same May 23, 2027 date, followed by equal monthly installments for three years, and expire on April 20, 2036. These awards are compensation-related grants rather than open‑market purchases.
PRECIGEN, INC. reported that President and CEO Helen Sabzevari received new equity awards. She was granted 410,000 Restricted Stock Units, each representing one share of common stock, and options on 1,366,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027 and then in equal monthly installments over three years, while the RSUs vest 25% on the same date and then in equal six‑month installments over three years. No shares were sold in these transactions.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah received new equity awards as part of his compensation. He was granted 118,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted options on 395,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years, aligning his incentives with the company’s longer-term performance.
Precigen, Inc. reported that Chief Commercial Officer Phil Tennant received new equity awards. On April 20, 2026, he was granted 115,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted 385,000 stock options with an exercise price of $4.11 per share, expiring on April 20, 2036.
The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years. After these grants, Tennant holds 115,000 RSUs and options covering 385,000 shares, all as direct ownership.
Precigen, Inc.’s Chief Financial Officer Harry Thomasian Jr. reported compensation-related equity grants. He received 120,000 Restricted Stock Units, each representing one share of Precigen common stock, and options on 399,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027, then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027, then in equal six‑month installments for three years. The filing shows no open‑market purchases or sales, only awards granted.
PRECIGEN, INC. director and 10% owner Randal J. Kirk reported multiple indirect open-market sales of Common Stock through entities he controls. In total, these entities sold 4,772,781 shares at a weighted average price of $3.30 per share in transactions on March 30, 2026, with individual prices ranging from $3.22 to $3.58.
The sales were made by vehicles including R.J. Kirk Declaration of Trust, various JPK, MGK and ZSK LLCs, the Kellie L. Banks (2009) Long Term Trust and Sunset 2020, LLC. After the transactions, reported indirect holdings included 80,672,818 shares by R.J. Kirk Declaration of Trust and 12,262,741 shares by Sunset 2020, LLC, along with additional positions at entities such as Kapital Joe, Lotus, Third Security and Parkview 2020. Mr. Kirk may be deemed to beneficially own these shares under Rule 13d-3 but disclaims beneficial ownership except to the extent of any pecuniary interest.
Precigen, Inc. major holder Randal J. Kirk and affiliated entities disclosed open-market sales of 4,772,781 shares of Common Stock on March 30, 2026, generating aggregate net proceeds of approximately $15,581,221. After these sales, Mr. Kirk reports beneficial ownership of 133,956,416 shares, or 35.9% of the company’s Common Stock, including 988,659 options and 16,666,667 warrants that are exercisable within sixty days. The R.J. Kirk Declaration of Trust reports 97,339,485 shares, or 26.1%, including 16,666,667 warrants, while Third Security, LLC reports 21,843,458 shares, or 5.9%. Percentage ownership is calculated using 353,928,672 shares outstanding as of February 15, 2026, adjusted for subsequent equity grants, vested restricted stock units, and Mr. Kirk’s exercisable options and warrants.
PGEN filed a Form 144 reporting proposed sales of Common Stock. The filing lists historical issuances, private placements, RSU vesting events and a secondary public offering with per-event share counts and dates from 03/01/2013 through 07/03/2018.